Status:
COMPLETED
Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19
Lead Sponsor:
University Hospital Schleswig-Holstein
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Based on the literature, it seems likely that a nutritional intervention with nicotinamide (a form of vitamin B3) can support the therapy of SARS-CoV-2 infection (COVID-19). A pilot phase of the COVit...
Eligibility Criteria
Inclusion
- The patient is of age (at least 18 years).
- SARS-CoV-2 infection confirmed by laboratory findings; the positive test must not date back more than 7 days.
- Relevant infection symptoms, e.g. in the respiratory or gastrointestinal tract.
- The patient has been able to give written consent via a website before any trial procedure is performed and can comply with the trial-dependent prerequisites and requirements.
Exclusion
- Current participation in another trial.
- Pregnancy or breastfeeding.
- Vaccination against SARS-CoV-2.
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 20 2022
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT04751604
Start Date
February 1 2021
End Date
October 20 2022
Last Update
November 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Schleswig-Holstein
Kiel, Schleswig-Holstein, Germany, 24105